13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001515070
Total reported value
$635.1M
$635.1M
34 檔
58.4%
In Q1 2026, Tetragon Partners GP Ltd's U.S. equity holdings reached a combined market value of $635.1M, distributed across 34 disclosed stock positions.
In Q1 2026, Tetragon Partners GP Ltd displayed an active expansion posture, initiating 10 new positions and adding to 16 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | PATH | Uipath Inc - Class A | Stock-Tech | 54.32% | -1.34% | +44.46% | |
| 2 | KGEI | Kolibri Global Energy Inc | Stock-Other | 7.28% | -1.95% | -1.44% | |
| 3 | WBD | Warner Bros Discovery Inc | Stock-Comm Services | 4.92% | -3.87% | — | |
| 4 | WK | Workiva Inc | Stock-Tech | 2.89% | -0.98% | +66.67% | |
| 5 | LYFT | Lyft Inc-a | Stock-Tech | 2.58% | -0.28% | — | |
| 6 | CXM | Sprinklr Inc-a | Stock-Other | 2.56% | -0.77% | — | |
| 7 | AUTL | Autolus Therapeutics PLC | Stock-Other | 2.55% | -0.16% | — | |
| 8 | CLDX | Celldex Therapeutics Inc | Stock-Other | 1.92% | -0.22% | +28.10% | |
| 9 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 1.81% | -0.46% | +104.42% | |
| 10 | ARWR | Arrowhead Pharmaceuticals In | Stock-Healthcare | 1.55% | +0.12% | +31.22% | |
| 11 | NKTR | Nektar Therapeutics | Stock-Other | 1.44% | -0.48% | +48.71% | |
| 12 | ANNX | Annexon Inc | Stock-Other | 1.39% | -0.27% | -36.41% | |
| 13 | PHVS | Pharvaris N.V. | Stock-Other | 1.22% | +0.39% | +13.87% | |
| 14 | ALKS | Alkermes plc | Stock-Healthcare | 1.10% | +0.47% | +13.19% | |
| 15 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 1.08% | +0.41% | +1.74% | |
| 16 | IMVT | Immunovant Inc | Stock-Other | 1.05% | +0.50% | +31.48% | |
| 17 | PRAX | Praxis Precision Medicines I | Stock-Other | 1.00% | -1.00% | EXIT | |
| 18 | KRYS | Krystal Biotech Inc | Stock-Healthcare | 0.99% | +0.16% | +66.48% | |
| 19 | DYN | Dyne Therapeutics Inc | Stock-Other | 0.91% | +0.34% | +4.09% | |
| 20 | AMLX | Amylyx Pharmaceuticals Inc | Stock-Other | 0.86% | +0.01% | +16.51% | |
| 21 | MBX | Mbx Biosciences Inc | Stock-Other | 0.84% | +0.93% | +1.50% | |
| 22 | DFTX | Definium Therapeutics Inc | Stock-Other | 0.73% | +1.40% | — | |
| 23 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 0.66% | -0.66% | EXIT | |
| 24 | HRMY | Harmony Biosciences Holdings | Stock-Other | 0.65% | +0.50% | +44.09% | |
| 25 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 0.64% | +1.20% | +72.47% | |
| 26 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 0.62% | +0.05% | — | |
| 27 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 0.61% | +0.60% | — | |
| 28 | MPLT | Maplight Therapeutics Inc | Stock-Other | 0.44% | -0.44% | EXIT | |
| 29 | RLAY | Relay Therapeutics Inc | Stock-Other | 0.35% | +1.33% | — | |
| 30 | SNOW | Snowflake Inc | Stock-Tech | 0.29% | +0.11% | — | |
| 31 | AARD | Aardvark Therapeutics Inc | Stock-Other | 0.23% | -0.23% | EXIT | |
| 32 | TECX | Tectonic Therapeutic Inc | Stock-Other | 0.23% | +0.02% | — | |
| 33 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 0.16% | +0.37% | — | |
| 34 | KPTI | Karyopharm Therapeutics Inc | Stock-Other | 0.11% | +0.28% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | KGEI | Kolibri Global Energy Inc | +1.5% | -1.44% | Trim |
| 2 | NKTR | Nektar Therapeutics | +0.8% | +48.71% | Add |
| 3 | AXSM | Axsome Therapeutics Inc | +0.8% | +104.42% | Add |
| 4 | CLDX | Celldex Therapeutics Inc | +0.5% | +28.10% | Add |
| 5 | KRYS | Krystal Biotech Inc | +0.4% | +66.48% | Add |
| 6 | ALKS | Alkermes plc | +0.3% | +13.19% | Add |
| 7 | ARWR | Arrowhead Pharmaceuticals In | +0.2% | +31.22% | Add |
| 8 | AMLX | Amylyx Pharmaceuticals Inc | +0.2% | +16.51% | Add |
| 9 | SLN | Silence Therapeutics Plc-adr | +0.2% | +72.47% | Add |
| 10 | WK | Workiva Inc | +0.2% | +66.67% | Add |
| 11 | IMVT | Immunovant Inc | +0.2% | +31.48% | Add |
| 12 | AGIO | Agios Pharmaceuticals Inc | +0.2% | +1.74% | Add |
| 13 | PHVS | Pharvaris N.V. | +0.1% | +13.87% | Add |
| 14 | HRMY | Harmony Biosciences Holdings | — | +44.09% | Add |
| 15 | MBX | Mbx Biosciences Inc | -0.1% | +1.50% | Add |
| 16 | DYN | Dyne Therapeutics Inc | -0.1% | +4.09% | Add |
| 17 | SNOW | Snowflake Inc | -0.2% | — | Unchanged |
| 18 | MPLT | Maplight Therapeutics Inc | -0.2% | -31.86% | Trim |
| 19 | PRAX | Praxis Precision Medicines I | -0.4% | -30.50% | Trim |
| 20 | ANNX | Annexon Inc | -0.8% | -36.41% | Trim |
| 21 | CXM | Sprinklr Inc-a | -1.1% | — | Unchanged |
| 22 | AUTL | Autolus Therapeutics PLC | -1.4% | — | Unchanged |
| 23 | LYFT | Lyft Inc-a | -1.5% | — | Unchanged |
| 24 | PATH | Uipath Inc - Class A | -6% | +44.46% | Add |
| 25 | WBD | Warner Bros Discovery Inc | — | NEW | New buy |
| 26 | RAPT | Rapt Therapeutics Inc | — | EXIT | Sold out |
| 27 | DFTX | Definium Therapeutics Inc | — | NEW | New buy |
| 28 | AM6 | Amicus Therapeutics Inc | — | EXIT | Sold out |
| 29 | SLNOEUR | Soleno Therapeutics Inc | — | NEW | New buy |
| 30 | ACAD | Acadia Pharmaceuticals Inc | — | NEW | New buy |
| 31 | IONS | Ionis Pharmaceuticals Inc | — | NEW | New buy |
| 32 | RLAY | Relay Therapeutics Inc | — | NEW | New buy |
| 33 | ZVRA | Zevra Therapeutics Inc | — | EXIT | Sold out |
| 34 | AARD | Aardvark Therapeutics Inc | — | NEW | New buy |
| 35 | TECX | Tectonic Therapeutic Inc | — | NEW | New buy |
| 36 | ✓ | Avadel Pharmaceuticals PLC ADR | — | EXIT | Sold out |
| 37 | RARE | Ultragenyx Pharmaceutical In | — | NEW | New buy |
| 38 | KPTI | Karyopharm Therapeutics Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Tetragon Partners GP Ltd reported a total U.S. public equity portfolio value of $635.1M across 34 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including PATH, KGEI, WBD) accounted for 58.4% of total reported equity market value during Q1 2026.
Top New Position Initiated
WBD
市值: $25.4M
Top Position Liquidated / Trimmed
RAPT
前期市值: $4.5M
During Q1 2026, Tetragon Partners GP Ltd's top holdings by market value included PATH (54.3%)、KGEI (7.3%)、WBD (4.9%). The largest single position, PATH, represented 54.3% of total portfolio value.
In Q1 2026, Tetragon Partners GP Ltd made 34 total portfolio adjustments, initiating 10 new buys, adding to 16 positions, trimming 4 holdings, and fully liquidating 4 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.